Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: A comparison of iron-sucrose and iron-dextran

Nephron - Clinical Practice

Volumn 118, Issue 3, 2011, Pages

  Stefánsson, Bergur V ^a,b   Haraldsson, Börje ^a   Nilsson, Ulf ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anemia; Ascorbyl free radical; Hemodialysis patients; Intravenous iron therapy; Oxidative stress

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FREE RADICAL; IRON DEXTRAN; TRANSFERRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; IRON KINETICS; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION;

ADULT; AGED; DEXTRANS; FEMALE; FERRIC COMPOUNDS; FREE RADICALS; HUMANS; IRON; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RENAL DIALYSIS;

EID: 79959801240     PISSN: 16602110     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000321645     Document Type: Article

References (55)

1. Nissenson AR, Strobos J: Iron deficiency in patients with renal failure. Kidney Int Suppl 1999; 69:S18-S21. (Pubitemid 29113579)
2. KDOQI NKF: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47:S11-S145.
3. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(suppl 2):ii1-ii47.
4. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32(suppl 1):9-16. (Pubitemid 41704982)
5. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in endstage renal disease. Circulation 2002; 106: 2212-2217. (Pubitemid 35222215)
6. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39-47. (Pubitemid 40038043)
7. Bayes B, Pastor MC, Bonal J, Foraster A, Romero R: Oxidative stress, inflammation and cardiovascular mortality in haemodialysis -role of seniority and intravenous ferrotherapy: Analysis at 4 years of follow-up. Nephrol Dial Transplant 2006; 21: 984-990.
8. Kuo K-L, Hung S-C, Wei Y-H, Tarng D-C: Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19: 1817-1826.
9. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289. (Pubitemid 38670014)
10. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012. (Pubitemid 35265481)
11. Eiselt J, Racek J, Opatrny K Jr, Trefil L, Stehlik P: The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. Blood Purif 2006; 24: 531-537. (Pubitemid 46039481)
12. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549. (Pubitemid 30115084)
13. Sezer MT, Akin H, Demir M, Erturk J, Aydin ZD, Savik E, Tunc N: The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients. J Nephrol 2007; 20: 196-203. (Pubitemid 47072403)
14. Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T, Miyanaka K, Miyoshi T, Shiraishi N, Nonoguchi H, Otagiri M, Tomita K: Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004; 66: 841-848. (Pubitemid 38982029)
15. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001; 37: 750-757. (Pubitemid 32268036)
16. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687. (Pubitemid 32208386)
17. Maruyama Y, Nakayama M, Yoshimura K, Nakano H, Yamamoto H, Yokoyama K, Lindholm B: Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2' -deoxyguanosine levels. Nephrol Dial Transplant 2007; 22: 1407-1412. (Pubitemid 47072230)
18. Stefánsson BV, Haraldsson B, Nilsson U: Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection. Free Radic Biol Med 2008; 45: 1302-1307.
19. Tiranathanagul K, Eiam-Ong S, Tosukhowong P, Praditpornsilpa K, Tungsanga K: Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients. Nephrology (Carlton) 2004; 9: 217-222. (Pubitemid 39318645)
20. Cavdar C, Temiz A, Yenicerioglu Y, Caliskan S, Celik A, Sifil A, Onvural B, Camsari T: The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 2003; 37: 77-82. (Pubitemid 36246219)
21. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H: Non-transferrinbound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J Am Soc Nephrol 2004; 15: 1648-1655. (Pubitemid 38679691)
22. Saglam F, Cavdar C, Uysal S, Cavdar Z, Camsari T: Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients. Ren Fail 2007; 29: 849-854. (Pubitemid 350139034)
23. Van Campenhout A, Van Campenhout C, Lagrou A, Manuel-y-Keenoy B: Iron-induced oxidative stress in haemodialysis patients: A pilot study on the impact of diabetes. Biometals 2008; 21: 159-170. (Pubitemid 351421984)
24. Anraku M, Kitamura K, Shintomo R, Takeuchi K, Ikeda H, Nagano J, Ko T, Mera K, Tomita K, Otagiri M: Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: A pilot study. Clin Biochem 2008; 41: 1168-1174.
25. De Vecchi AF, Novembrino C, Lonati S, Ippolito S, Bamonti F: Two different modalities of iron gluconate i.v. administration: Effects on iron, oxidative and inflammatory status in peritoneal dialysis patients. Nephrol Dial Transplant 2007; 22: 1709-1713. (Pubitemid 47073773)
26. Michelis R, Sela S, Kristal B: Intravenous iron-gluconate during haemodialysis modifies plasma β2 -microglobulin properties and levels. Nephrol Dial Transplant 2005; 20: 1963-1969. (Pubitemid 41222615)
27. Leehey DJ, Palubiak DJ, Chebrolu S, Agarwal R: Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: A pilot study. Nephrol Dial Transplant 2005; 20: 135-140. (Pubitemid 40207618)
28. Hodkova M, Kalousova M, Dusilova-Sulkova S, Malbohan IM, Zima T: Intravenous iron gluconate administration increases circulating PAPP-A in hemodialysis patients. Ren Fail 2005; 27: 707-711. (Pubitemid 41748123)
29. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, Shasha SM, Kristal B: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18: 924-930. (Pubitemid 36592534)
30. Driss F, Vrtovsnik F, Katsahian S, Michel C, Baron G, Kolta A, Sedrati N, Mentre F, Mignon F, Cabantchik I, Grandchamp B: Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients. Nephron Clin Pract 2005; 99:c63-c67. (Pubitemid 40463247)
31. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-350. (Pubitemid 46327902)
32. Malindretos P, Sarafidis PA, Rudenco I, Raptis V, Makedou K, Makedou A, Grekas DM: Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: A comparative study between iron sucrose and iron dextran. Am J Nephrol 2007; 27: 572-579. (Pubitemid 350014944)
33. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001; 60: 1525-1531. (Pubitemid 32960048)
34. Kozlov AV, Yegorov D, Vladimirov YA, Azizova OA: Intracellular free iron in liver tissue and liver homogenate: Studies with electron paramagnetic resonance on the formation of paramagnetic complexes with Desferal and nitric oxide. Free Radic Biol Med 1992; 13: 9-16.
35. Hagen WR: Biomolecular EPR Spectroscopy. New York, Taylor & Francis, 2009, pp 3-228.
36. Ahotupa M, Ruutu M, Mantyla E: Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem 1996; 29: 139-144. (Pubitemid 26115431)
37. Erel O: A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277-285. (Pubitemid 38314881)
38. Reznick AZ, Packer L: Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233: 357-363.
39. Siedel J, Wahlefeld AW, Ziegenhorn J: Improved, ferrozine-based reagent for the determination of serum iron (transferring iron) without deproteinization. Clin Chem 1983; 30: 975.
40. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103. (Pubitemid 34701216)
41. Seligman PA, Schleicher RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999; 45: 898-901. (Pubitemid 29266622)
42. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 2004; 19: 561-565. (Pubitemid 38263113)
43. Hider RC: Nature of non-transferrin-bound iron. Eur J Clin Invest 2002; 32(suppl 1):50-54.
44. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. ironsaccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834.
45. Sunder-Plassmann G, Horl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1797-1802. (Pubitemid 26297566)
46. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM: 'oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit® ) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824.
47. Milman N: Iron therapy in patients undergoing maintenance hemodialysis. Acta Med Scand 1976; 200: 315-319.
48. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin-bound iron in dialysis patients. Eur J Clin Invest 2002; 32(suppl 1):42-49. (Pubitemid 41704987)
49. Wang S, Geraci G, Kuhlmann MK, Levin NW, Handelman GJ: Chemical reactions of vitamin C with intravenous-iron formulations. Nephrol Dial Transplant 2008; 23: 120-125. (Pubitemid 351767371)
50. Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B: Intravenous iron preparations and ascorbic acid: Effects on chelatable and bioavailable iron. Kidney Int 2005; 67: 1161-1170. (Pubitemid 41623343)
51. Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H: Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 2003; 65: 1973-1978. (Pubitemid 36629581)
52. Van Wyck DB: Labile iron: Manifestations and clinical implications. J Am Soc Nephrol 2004; 15:S107-S111. (Pubitemid 39578824)
53. Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ: Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. Biometals 2003; 16: 425-433. (Pubitemid 36356773)
54. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382. (Pubitemid 43159991)
55. Auerbach M, Al Talib K: Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008; 73: 528-530. (Pubitemid 351264124)